Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 0.13
- Piotroski Score 6.00
- Grade Sector Perform
- Symbol (BHC)
- Company Bausch Health Companies Inc.
- Price $7.97
- Changes Percentage (-2.63%)
- Change -$0.22
- Day Low $7.96
- Day High $8.19
- Year High $11.46
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
- Last Earnings 11/04/2010
- Ex-Dividend for 5/16 Dividend 11/10/2010
- Dividend Payable 12/22/2010
- Today N/A
- Next Earnings (Estimated) 02/19/2025
- Fiscal Year End N/A
- Average Stock Price Target $9.00
- High Stock Price Target $16.00
- Low Stock Price Target $7.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.24
- Trailing P/E Ratio -5.06
- Forward P/E Ratio -5.06
- P/E Growth -5.06
- Net Income $-592,000,000
Income Statement
Quarterly
Annual
Latest News of BHC
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
National Bank Holdings' (NYSE:NBHC) Upcoming Dividend Will Be Larger Than Last Year's
National Bank Holdings Corporation will increase its dividend to $0.29, yielding 2.6%, maintaining a 10-year dividend history. With a growing EPS and stable distributions, it presents a strong income ...
By Yahoo! Finance | 3 weeks ago -
Retail investors in Pathfinder Bancorp, Inc. (NASDAQ:PBHC) are its biggest bettors, and their bets paid off as stock gained 18% last week
Pathfinder Bancorp has 7 investors owning a majority stake of 50%, with retail investors holding the largest share at 30%. The company's market cap hit US$100m with a 18% stock gain....
By Yahoo! Finance | 1 month ago -
Bausch Health Companies (NYSE:BHC shareholders incur further losses as stock declines 4.4% this week, taking three-year losses to 72%
Bausch Health Companies Inc. stock has seen a 26% increase in the last month, but a staggering 72% decline over three years. The company's revenue growth is slow, and profitability remains a concern....
By Yahoo! Finance | 1 month ago
